# REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have also been amended to delete multiple dependencies and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By _____
Gerald M. Murphy, Jr., #28,977

GMM/cqc
1110-0284P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment: Version With Markings Showing Changes Made

(Rev. 01/22/01)

3

VERSION WITH MARKINGS SHOWING CHANGES MADE

The specification has been amended to provide cross-referencing to the International Application.

The claims have been amended as follows:

11.   (Amended) A hybridoma that produces the antibody according to [any one of claims 5 to 9]claim 5.

Table 1 on page 56 has been amended as follows:

Table 1

SPOT No.	Amino Acid Sequence	Intensity of Coloring
44	Ala Cys Ala Arg Ser Thr Leu Ser Val Gly(SEQ ID NO:8)	–
45	Ala Arg Ser Thr Leu Ser Val Gly Val Ser(SEQ ID NO:9)	++
46	Ser Thr Leu Ser Val Gly Val Ser Gly Thr(SEQ ID NO:10)	+

Table 2 on page 57 has been amended as follows:

Table 2

SPOT No.	Amino Acid Sequence	Intensity of Coloring
35	Val Pro Gly ThHr Ala Leu Pro His Glu Gly(SEQ ID NO:11)	+
36	Gly ThHr Ala Leu Pro His Glu Gly Ser Met(SEQ ID NO:12)	++
37	Ala Leu Pro His Glu Gly Ser Met Asn Ser(SEQ ID NO:13)	+